Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Librera OncoLink / Repaso de Diarios / Cánceres Pediátricos
Jenkin D, Danjoux C, Greenberg M
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Reviewers: John Han-Chih Chang, MD
Source: Medical and Pediatric Oncology 1998; Volume 31: pages 506 - 511.
This article attempts to review the experience of the primary brain tumor patients treated with surgery and RT at the University of TorontoCentres. Focus was mainly on quality of life, in particular neurocognitive sequelae of treatment.
| Neurocognitive Deficit | Age less than 2 years old | Aged 2 - 4 years |
| Major Ambulation Difficulty | 21% | 10% |
| Major Visual Defect | 35% | 18% |
| Blindness | 19% | 4% |
| Moderate to Severe Hearing Loss | 11% | 15% |
| In Regular School System | 48% | 46% |
| In Special or Blind Education | 52% | 51% |
Table 1 has a breakdown by age and neurocognitive deficit, which I have condensed above. Data on the 23 that had survived and were olderthan 21 yielded only 3 having acquired a university and 2 a community college degree. Fourteen had not received a "higher education." This isnot too far from the national average in Canada, which has an 11% rate of university graduates in its adult population.
Surgical/tumor complications were also seen in 28% of 93 patients currently alive. These may have had an effect on the deficits seen. Thecomplications include shunt revisions, meningitis, subdural effusions and re-exploration.
The authors state that over 80% of the adult survivors are capable of independent living. One third are able to live a normal life and compete forgainful employment at a normal level. But, nearly 40% will have some major neurocognitive deficit.
One drawback of this article and of most reviews on neurocognitive sequelae of treatment in children is the lack of standardized testing beforesurgery and/or RT. That testing could have been truly revealing as to whether the tumor, surgery or the RT was the culprit behind the deficit.On the other hand, such tests performed in younger children may be inherently inaccurate. Another criticism is that some of the data wereobtained from questionnaires and phone calls. Finally, little was made about a comparison to those with primary brain tumors who did notreceive RT. Hopefully, future and current randomized trials will answer not only OS data, but quality of life on those who do and those thatnever receive RT.
Overall, this article did suggest that not all survivors of childhood primary brain tumors perform poorly in neurocognitive functioning. Asignificant proportion can function normally in society. But, it does make us aware of the critical issue of neurologic toxicity from definitivetreatment. Limiting this morbidity without compromising survival outcome is the necessary next step.
Dr. Hill-Kayser talks about working in oncology care and how her line of work can be particularly rewarding. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

